The Head of the National Cancer Research Center visited Pars Isotope Co.

Prof. Mohammad Ismail Akbari, the head of the National Cancer Research Center, visited Pars Isotope on February 22, 2022, and had a close scientific meeting with Pars Isotope’s expert staff.
According to the Pars Isotope’s public relations report, the head of the country’s cancer research center had a visit to the production line of Pars Isotope radiopharmaceutical products and was closely acquainted with the production procedures and got familiar with new radiopharmaceutical products of Pars Isotope Co. in the field of cancer diagnosis and treatment.
This visit, which lasted more than two hours, was initially hosted by the CEO of Pars Isotope Co., and then the production line of Pars Isotope diagnostic and therapeutic radiopharmaceuticals was visited. Professor Akbari had a scientific discussion with Pars Isotope Co. specialists about the uses of radiopharmaceuticals in the diagnosis and treatment of different types of cancer, and he called for continued cooperation between Pars Isotope and the National Cancer Research Center.
Prof. Mohammad Ismail Akbari is the head of the National Cancer Research Center, the director of the Iranian Medical Education Association, the Chairman of the Board of Tobacco-Free Life Association, the President of the COACH Institute and a member of the National Cancer Control Committee. He gained his subspecialty degree in surgical endocrinology and oncology from the US, and he is currently working as a professor in the surgery department of Shahid Beheshti University of Medical Sciences. During his speech, Professor Akbari pointed out that cancer is one of the diseases that is rooted in the social, cultural and economic structure of the society, as well as social and individual behaviors, as well as the functioning of cells and their constituent elements. “We have approximately 300,000 to 350,000 patients suffering from cancer in the country, and Pars Isotope has a great role in the diagnosis and treatment procedure of these diseases through the manufacturing of radiopharmaceuticals” he said.